MP33-19 INTRADUCTAL CARCINOMA OF THE PROSTATE IN THE ERA OF MPMRI-TARGETED PROSTATE BIOPSIES: CLINICAL, PATHOLOGIC AND MRI CHARACTERISTICS

Résumé fourni par la source

You have accessJournal of UrologyCME1 May 2022MP33-19 INTRADUCTAL CARCINOMA OF THE PROSTATE IN THE ERA OF MPMRI-TARGETED PROSTATE BIOPSIES: CLINICAL, PATHOLOGIC AND MRI CHARACTERISTICS Jonathan Fainberg, Christine Chen, Johnson Chen, Adithya Balasubramanian, Christopher Barbieri, Leo Dreyfus, Beerinder Karir, Francesca Khani, Daniel Margolis, Timothy McClure, Himanshu Nagar, and Brian Robinson Jonathan FainbergJonathan Fainberg More articles by this author , Christine ChenChristine Chen More articles by this author , Johnson ChenJohnson Chen More articles by this author , Adithya BalasubramanianAdithya Balasubramanian More articles by this author , Christopher BarbieriChristopher Barbieri More articles by this author , Leo DreyfusLeo Dreyfus More articles by this author , Beerinder KarirBeerinder Karir More articles by this author , Francesca KhaniFrancesca Khani More articles by this author , Daniel MargolisDaniel Margolis More articles by this author , Timothy McClureTimothy McClure More articles by this author , Himanshu NagarHimanshu Nagar More articles by this author , and Brian RobinsonBrian Robinson More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002587.19AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Since 2018, there is increasing adoption of mpMRI to detect prostate cancer, particularly in the pre-biopsy setting. Recent studies showed that mpMRI is a sensitive tool for detecting cancers harboring intraductal carcinoma of the prostate (IDC-P). The presence of IDC-P has been associated with adverse pathological features and worse clinical outcomes. The goals of this study were to 1) determine frequency of IDC-P detected on biopsy in the mpMRI era and 2) assess the MRI and pathologic characteristics of biopsy proven IDC-P. METHODS: The pathology archives were retrospectively analyzed under an IRB-approved protocol. All prostate biopsy and radical prostatectomy (RP) reports were reviewed for the presence or absence of IDC-P, Grade Group, pathological stage, presence of MRI targeted biopsies and MRI characteristics. We reviewed cases from 2018-2020 (MRI biopsy years) and analyzed MRI features of all IDC-P proven biopsies. RESULTS: Between the years 2018-2020 86 patients had an mpMRI and IDC-P on prostate biopsy or prostatectomy specimen. Pathologic characteristics revealed: six (7%) GG1, thirty-two (37%) GG2, twenty-one (24%) GG3, three (4%) GG4, and twenty-four (28%) GG5. When IDC-P was present on biopsy, it appeared in 79% of the MRI targets, accounting for over half (52%) of all IDC-P cases detected on biopsy. In our cohort, 60 patients had IDC-P detected in the MRI target or in the systematic sextant concordant with an MRI lesion. 90% of these lesions were PIRADS 4 or 5 [25% PIRADS 4; 65% PIRADS 5]. 93% of the lesions were in the peripheral zone (PZ). Average lesion size was 1.97 cm. Average ADC mean was 723.9 and 80% of lesions were positive for dynamic contrast enhancement (DCE). 93% of these lesions were >GG2. CONCLUSIONS: These findings suggest that when IDC-P is present on biopsy, it is typically visible on pre-biopsy MRI as a targetable lesion that is PIRADS 4 or 5. These lesions tend to be large, positive for DCE and have low ADC scores. Cancers harboring IDC-P that are detected in the MRI era continue to be associated with aggressive radiologic and pathologic features. Further studies are needed to better characterize the mpMRI characteristics of IDC-P. Source of Funding: None © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e577 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Jonathan Fainberg More articles by this author Christine Chen More articles by this author Johnson Chen More articles by this author Adithya Balasubramanian More articles by this author Christopher Barbieri More articles by this author Leo Dreyfus More articles by this author Beerinder Karir More articles by this author Francesca Khani More articles by this author Daniel Margolis More articles by this author Timothy McClure More articles by this author Himanshu Nagar More articles by this author Brian Robinson More articles by this author Expand All Advertisement PDF DownloadLoading ...

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.